# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY

I Background Information:

# B Applicant

INOVA Diagnostics, Inc.

# C Proprietary and Established Names

Aptiva APS IgG Reagent Aptiva APS IgM Reagent

D Regulatory Information

<table><tr><td rowspan=1 colspan=1>ProductCode(s)</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>MIDMSV</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 866.5660  MultipleAutoantibodies Immunological Test System</td><td rowspan=1 colspan=1>IM-Immunology</td></tr></table>

II Submission/Device Overview:

A Purpose for Submission: New Device

# B Measurand:

Aptiva APS IgG Reagent Anti-cardiolipin IgG autoantibodies (aCL IgG) Anti-beta 2 glycoprotein $1 \ \mathrm { I g G }$ autoantibodies (aβ2GPI IgG)

Aptiva APS IgM Reagent Anti-cardiolipin IgM autoantibodies (aCL IgM) Anti-beta 2 glycoprotein $1 \ \mathrm { I g M }$ autoantibodies (aβ2GPI IgM)

# C Type of Test:

Semi quantitative, Particle-based multi-analyte assay

# III Intended Use/Indications for Use:

A Intended Use(s): See Indications for Use below.

# B Indication(s) for Use:

# Aptiva APS IgG Reagent

The Aptiva APS IgG Reagent is an immunoassay utilizing particle-based multi-analyte technology for the semi-quantitative determination of anti-cardiolipin (aCL) and anti-beta 2 glycoprotein 1 (aβ2GPI) IgG autoantibodies in human serum as an aid in the diagnosis of primary and secondary antiphospholipid syndrome (APS), when used in conjunction with other clinical and laboratory findings.

The Aptiva APS IgG Reagent is intended for use with the Aptiva System.

# Aptiva APS IgM Reagent

The Aptiva APS IgM Reagent is an immunoassay utilizing particle-based multi-analyte technology for the semi-quantitative determination of anti-cardiolipin (aCL) and anti-beta 2 glycoprotein 1 $( \mathsf { a } \mathsf { \beta } 2 \mathsf { G P I } )$ ) IgM autoantibodies in human serum as an aid in the diagnosis of primary and secondary antiphospholipid syndrome (APS), when used in conjunction with other clinical and laboratory findings.

The Aptiva APS IgM Reagent is intended for use with the Aptiva System.

C Special Conditions for Use Statement(s): Rx - For Prescription Use Only D Special Instrument Requirements: Inova Diagnostics Aptiva System (K193604)

# IV Device/System Characteristics:

A Device Description:

Aptiva APS IgG Reagent and Aptiva APS IgM Reagent utilize particle-based multi-analyte technology (PMAT) in a cartridge format. Both assays are run on Inova Diagnostics Aptiva System.

The Aptiva APS IgG Reagent contains one cartridge with the following reagents for 200 determinations:

• APS IgG Beads ( $\mathrm { 1 } { \times } 0 . 5 \mathrm { m L }$ ): Paramagnetic beads coated with native Cardiolipin (CL) plus $\beta 2 \mathrm { G P I }$ antigens, native $\beta 2 \mathrm { G P I }$ antigen, AffiniPure goat polyclonal anti-human $\mathrm { I g G }$ , and stabilizer   
• Assay Buffer $\mathrm { 1 } { \times } \mathrm { 1 } 7 \mathrm { m L }$ : Containing protein stabilizers and preservatives PE Tracer IgG $\mathrm { 1 } { \times } \mathrm { 1 } 7 \mathrm { m L }$ ): Phycoerythrin (PE) labeled goat anti-human IgG antibody with stabilizer and preservative   
• Rehydration Buffer ( $1 { \times } 6 . 5 ~ \mathrm { m L }$ ): Containing protein stabilizer and preservative

# Materials Required but Not Provided

• Aptiva APS IgG Calibrators: 3 Calibrators $( 2 { \times } 0 . 3 \mathrm { m L / e a c h } )$ of human antibodies, each contains human aCL IgG and aβ2GPI IgG in stabilizers and preservatives;   
Aptiva APS IgG Controls: 2 Controls $( 2 { \times } 0 . 5 ~ \mathrm { m L / e a c h } )$ of human antibodies, each contain human aCL IgG and aβ2GPI IgG in stabilizers and preservatives

The Aptiva APS IgM Reagent kit contains one cartridge with the following reagents for 200 determinations:

• APS IgM Beads ( $1 { \times } 0 . 5 ~ \mathrm { m L }$ ): Paramagnetic beads coated with native Cardiolipin (CL) plus $\beta 2 \mathrm { G P I }$ antigens, native $\beta 2 \mathrm { G P I }$ antigen, AffiniPure goat polyclonal anti-human IgM, and stabilizer   
• Assay Buffer $\mathrm { 1 } { \times } 1 7 \mathrm { m L }$ : Containing protein stabilizers and preservatives   
PE Tracer IgM $( 1 \times 1 7 ~ \mathrm { m L } )$ ): PE labeled goat anti-human IgM antibody with stabilizer and preservative   
• Rehydration Buffer $\mathrm { 1 } { \times } 6 . 5 \mathrm { m L }$ ): Containing protein stabilizer and preservative

# Materials Required but Not Provided

• Aptiva APS IgM Calibrators: 3 Calibrators $( 2 { \times } 0 . 3 \mathrm { m L / e a c h } )$ of human antibodies, each contains human aCL IgM and aβ2GPI IgM in stabilizers and preservatives   
• Aptiva APS IgM Controls: 2 Controls $( 2 { \times } 0 . 5 ~ \mathrm { m L / e a c h } )$ of human antibodies, each contains human aCL IgM and aβ2GPI IgM in stabilizers and preservatives

# B Principle of Operation:

Both the Aptiva APS IgG Reagent and Aptiva APS IgM Reagent utilize particle based multianalyte technology (PMAT) in a cartridge format. Both the Aptiva APS IgG Reagent and the

Aptiva APS IgM Reagent contain two different populations of particles: one particle population coated with cardiolipin along with human purified $\mathsf { \beta 2 G P I }$ and another particle population coated with only human purified $\beta 2 \mathrm { G P I }$ antigen. The two analyte microparticles, along with the control microparticle, are stored in the reagent cartridge.

The Aptiva System dilutes the sample 1:8, then combines an aliquot of diluted sample, and reagent into a cuvette. After incubation at $3 7 ^ { \circ } \mathrm { C }$ and followed with a wash cycle, conjugated antihuman IgG or $\mathrm { I g M }$ antibodies are added to the particles. Following the incubation of this mixture at $3 7 ^ { \circ } \mathrm { C }$ , excess conjugate is removed in another wash cycle, and the particles are re-suspended in system fluid. Multiple images are generated by the system to identify and count the two unique analyte particles, as well as determine the amount of conjugate on each particle. A third particle, coated with goat anti-human $\mathrm { I g G }$ or $\mathrm { I g M }$ antibodies, is present in the reagent as a control to flag low concentrations of $\mathrm { I g G }$ or $\mathrm { I g M }$ in the sample as an assay verification step. The median fluorescent intensity (MFI) for each analyte is proportional to the concentration of conjugate bound to human IgG or IgM, which is proportional to the concentration of IgG or IgM antibodies bound to the corresponding particle population. The system uses the MFI from at least 50 particles of each population. The identity of the particles is determined by the unique signature of the particles.

Each analyte in the Aptiva APS IgG Reagent and the Aptiva APS IgM Reagent is assigned a predefined lot specific master curve. The analyte specific master curve is stored on the reagent cartridge radio frequency identification (RFID) label. Based on results obtained by running calibrators (supplied separately), the system creates individual working curves. Working curves are used by the software to calculate Fluorescent Light Units (FLU) for each analyte from the MFI values obtained for each sample.

# V Substantial Equivalence Information:

# A Predicate Device Name(s):

For Aptiva APS IgG Reagent: HemosIL AcuStar Cardiolipin IgG QUANTA Lite β2GPI IgG ELISA

For Aptiva APS IgM Reagent: HemosIL AcuStar Cardiolipin IgM HemoIL AcuStar anti- $\cdot \beta 2$ Glycoprotein-I IgM

# B Predicate 510(k) Number(s):

K092181 - HemosIL AcuStar Cardiolipin IgG; HemosIL AcuStar Cardiolipin IgM  
K970551 - QUANTA Lite β2GPI IgG ELISA  
K091556 - HemosIL AcuStar anti- $\cdot \beta 2$ Glycoprotein-I IgM

C Comparison with Predicate(s):

<table><tr><td colspan="1" rowspan="1">Device &amp;PredicateDevice(s):</td><td colspan="1" rowspan="1">K223093New Device</td><td colspan="1" rowspan="1">K092181Predicate</td><td colspan="1" rowspan="1">K970551Predicate</td></tr><tr><td colspan="1" rowspan="1">Device TradeName</td><td colspan="1" rowspan="1">Aptiva APS IgG Reagent</td><td colspan="1" rowspan="1">HemosIL AcuStarCardiolipin IgG</td><td colspan="1" rowspan="1">QUANTA Lite β2GPIIgG ELISA</td></tr><tr><td colspan="4" rowspan="1">General Device Characteristic Similarities</td></tr><tr><td colspan="1" rowspan="1">Intended Use/Indicationsfor Use</td><td colspan="1" rowspan="1">The Aptiva APS IgG Reagentis an immunoassay utilizingparticle-based multi-analytetechnology for the semi-quantitative determination ofanti-cardiolipin (aCL) andanti-beta 2 glycoprotein 1(aβ2GPI) IgG autoantibodiesin human serum as an aid inthe diagnosis of primary andsecondary antiphospholipidsyndrome (APS), when usedin conjunction with otherlaboratory findings. TheAptiva APS IgG Reagent isintended for use with theAptiva System.</td><td colspan="1" rowspan="1">Fully automatedchemiluminescentimmunoassay for thesemi-quantitativemeasurement of anti-cardiolipin (aCL) IgGantibodies in humancitrate plasma andserum on the BIO-FLASH instrument asan aid in the diagnosisof thrombotic disordersrelated to primary andsecondaryantiphospholipidsyndrome (APS), whenused in conjunctionwith other laboratoryand clinical findings.</td><td colspan="1" rowspan="1">A semi-quantitativeenzyme linkedimmunoassay fordetecting IgG classautoantibody to β2glycoprotein I (β2 GPI)for use as an aid in thediagnosis of certainautoimmune diseasethrombotic disorders,such as those secondaryto systemic lupuserythematosus (SLE) orother lupus-likethrombotic diseases.</td></tr><tr><td colspan="1" rowspan="2">Antigen</td><td colspan="1" rowspan="1">Bovine cardiolipin antigen</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">N/A</td></tr><tr><td colspan="1" rowspan="1">Purified human β2GPI</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">QualityControl</td><td colspan="1" rowspan="1">2 controls(sold separately)</td><td colspan="1" rowspan="1">Same(sold separately)</td><td colspan="1" rowspan="1">Same(included in the kit)</td></tr><tr><td colspan="4" rowspan="1">General Device Characteristic Differences</td></tr><tr><td colspan="1" rowspan="1">Solid Phase</td><td colspan="1" rowspan="1">Paramagnetic microparticles</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">96-well polystyrene plate</td></tr><tr><td colspan="1" rowspan="1">Assay Format</td><td colspan="1" rowspan="1">Fluorescent immunoassay</td><td colspan="1" rowspan="1">Chemiluminescentimmunoassay</td><td colspan="1" rowspan="1">Enzyme-linkedimmunosorbent assay</td></tr><tr><td colspan="1" rowspan="1">Instrumentation</td><td colspan="1" rowspan="1">INOVA Aptiva System</td><td colspan="1" rowspan="1">BIO-FLASHInstrument</td><td colspan="1" rowspan="1">Manual, ELISA reader</td></tr><tr><td colspan="1" rowspan="1">Sample Type</td><td colspan="1" rowspan="1">Human Serum</td><td colspan="1" rowspan="1">Human serum andcitrated plasma</td><td colspan="1" rowspan="1">Human serum</td></tr><tr><td colspan="1" rowspan="1">Conjugate</td><td colspan="1" rowspan="1">Phycoerythrin conjugatedpolyclonal anti-human IgGantibody</td><td colspan="1" rowspan="1">Isoluminol conjugatedmonoclonal anti-humanIgG antibody</td><td colspan="1" rowspan="1">Anti-human IgGhorseradish peroxidase(HRP)</td></tr><tr><td colspan="1" rowspan="1">Units</td><td colspan="1" rowspan="1">Fluorescent light units (FLU)</td><td colspan="1" rowspan="1">ChemiluminescentUnits</td><td colspan="1" rowspan="1">Standard β2GPI IgGUnits (SGU)</td></tr><tr><td colspan="1" rowspan="1">ResultInterpretation</td><td colspan="1" rowspan="1">Negative: &lt;5.00 FLUPositive: ≥5.00 FLU</td><td colspan="1" rowspan="1">Negative: &lt;20 U/mLPositive: ≥20 U/mL</td><td colspan="1" rowspan="1">20.0 SGU as cut-off</td></tr><tr><td colspan="1" rowspan="2">AnalyticalMeasuringInterval</td><td colspan="1" rowspan="1">0.29328.94 FLU (aCL IgG)</td><td colspan="1" rowspan="1">2.6 - 2024.0 U/mL</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">0.21256.70 FLU (aβ2GPI IgG)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">9.4 - 150.0 SGU</td></tr><tr><td colspan="1" rowspan="1">Calibration</td><td colspan="1" rowspan="1">Lot specific Master Curve + 3calibrators (sold separately)</td><td colspan="1" rowspan="1">2 calibrator levels(included in test kit)</td><td colspan="1" rowspan="1">1 calibrator diluted to a5-point standard curve(included in test kit)</td></tr></table>

# Aptiva APS IgM Reagent

<table><tr><td colspan="1" rowspan="1">Device &amp;PredicateDevice(s):</td><td colspan="1" rowspan="1">K223095New Device</td><td colspan="1" rowspan="1">K092181Predicate</td><td colspan="1" rowspan="1">K091556Predicate</td></tr><tr><td colspan="1" rowspan="1">Device TradeName</td><td colspan="1" rowspan="1">Aptiva APS IgM Reagent</td><td colspan="1" rowspan="1">HemosIL AcuStarCardiolipin IgM</td><td colspan="1" rowspan="1">HemosIL AcuStar anti-β2 Glycoprotein-I IgM</td></tr><tr><td colspan="3" rowspan="1">General Device Characteristic Similarities</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Intended Use/Indications forUse</td><td colspan="1" rowspan="1">The Aptiva APS IgM Reagentis an immunoassay utilizingparticle-based multi-analytetechnology for the semi-quantitative determination ofanti-cardiolipin (aCL) andanti-beta 2 glycoprotein 1(aβ2GPI) IgM autoantibodiesin human serum as an aid inthe diagnosis of primary andsecondary antiphospholipidsyndrome (APS), when usedin conjunction with otherlaboratory findings.The Aptiva APS IgM Reagentis intended for use with theAptiva System.</td><td colspan="1" rowspan="1">Fully automatedchemiluminescentassay for the semi-quantitativemeasurement of anti-cardiolipin (aCL) IgMantibodies in humancitrated plasma andserum on the BIO-FLASH instrument, asan aid in the diagnosisof thrombotic disordersrelated to primary andsecondaryantiphospholipidsyndrome (APS), whenused in conjunctionwith other laboratoryand clinical findings.</td><td colspan="1" rowspan="1">Fully automatedchemiluminescentimmunoassay for thesemi-quantitativemeasurement of anti-β2glycoprotein-I (anti-β2GPI) IgM antibodiesin human citratedplasma and serum onthe BIO-FLASHinstrument as an aid inthe diagnosis ofthrombotic disordersrelated to primary andsecondaryantiphospholipidsyndrome (APS), whenused in conjunction withother laboratory andclinical findings.</td></tr><tr><td colspan="1" rowspan="1">Solid phase</td><td colspan="1" rowspan="1">Paramagnetic microparticles</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="2">Antigen</td><td colspan="1" rowspan="1">Bovine cardiolipin antigen</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">N/A</td></tr><tr><td colspan="1" rowspan="1">Purified human β2GPI</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Quality Control</td><td colspan="1" rowspan="1">2 control levels(sold separately)</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="4" rowspan="1">General Device Characteristic Differences</td></tr><tr><td colspan="1" rowspan="1">Sample Type</td><td colspan="1" rowspan="1">Human serum</td><td colspan="2" rowspan="1">Human serum and citrated plasma</td></tr><tr><td colspan="1" rowspan="1">Assay Format</td><td colspan="1" rowspan="1">Fluorescent immunoassay</td><td colspan="2" rowspan="1">Chemiluminescent immunoassay</td></tr><tr><td colspan="1" rowspan="1">Instrumentation</td><td colspan="1" rowspan="1">INOVA Aptiva System</td><td colspan="2" rowspan="1">BIO-FLASH instrument</td></tr><tr><td colspan="1" rowspan="1">Conjugate</td><td colspan="1" rowspan="1">Phycoerythrin conjugatedpolyclonal anti-human IgMantibody</td><td colspan="2" rowspan="1">Isoluminol conjugated monoclonal anti-humanIgM antibody</td></tr><tr><td colspan="1" rowspan="1">Units</td><td colspan="1" rowspan="1">Fluorescent light units</td><td colspan="2" rowspan="1">Chemiluminescent units</td></tr><tr><td colspan="1" rowspan="1">ResultInterpretation</td><td colspan="1" rowspan="1">Negative: &lt;5.00 FLUPositive: ≥5.00 FLU</td><td colspan="2" rowspan="1">Negative: &lt;20 U/mLPositive: ≥20 U/mL</td></tr><tr><td colspan="1" rowspan="2">AnalyticalMeasuringInterval</td><td colspan="1" rowspan="1">0.1114.68 FLU (aCL IgM)</td><td colspan="1" rowspan="1">1.0 - 774.0 U/mL</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">0.1 95.86 FLU (aβ2GPI IgM)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1.1- 841 U/mL</td></tr><tr><td colspan="1" rowspan="1">Calibration</td><td colspan="1" rowspan="1">Lot specific Master Curve + 3calibrators (sold separately)</td><td colspan="2" rowspan="1">Two calibrator levels (included in test kit)</td></tr></table>

# VI Standards/Guidance Documents Referenced:

The following Clinical and Laboratory Standards Institute (CLSI) guidelines were used:

CLSI EP05-A3: Evaluation of Precision of Quantitative Measurement Procedures, Approved Guideline – Third Edition.   
• CLSI EP06-Ed2: Evaluation of the Linearity of Quantitative Measurement Procedures – Second Edition   
• CLSI EP07-A3: Interference Testing in Clinical Chemistry – Third Edition.   
• CLSI EP12-A2: User Protocol for Evaluation of Qualitative Test Performance – Second Edition.   
• CLSI EP17-A2: Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures, Approved Guideline – Second Edition.   
• CLSI EP25-A: Evaluation of Stability of In Vitro Diagnostic Reagents, Approved Guideline   
• CLSI EP28-A3c: Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory, Approved Guideline – Third Edition.   
• CLSI EP37: Supplemental Tables for Interference Testing in Clinical Chemistry   
• CLSI EP39: A Hierarchical Approach to Selecting Surrogate Samples for the Evaluation of In Vitro Medical Laboratory Tests

# VII Performance Characteristics (if/when applicable):

A Analytical Performance:

# 1. Precision/Reproducibility:

Precision and reproducibility of the Aptiva APS IgG Reagent and the Aptiva APS IgM Reagent were evaluated in accordance with the CLSI guideline EP05-A3.

# Within-Laboratory Precision:

Within-lab precision of the Aptiva APS IgG reagent was performed with by testing seven serum samples containing various concentrations of aCL IgG, aβ2GPI IgG, aCL IgM and aβ2GPI IgM autoantibodies. All samples were run in duplicate, twice a day, for 20 days using single lot of reagents on single instrument. Data was analyzed for repeatability (withinrun), between-run, between-day and within-laboratory precision. Results are summarized below.

# Aptiva APS IgG Reagent

<table><tr><td rowspan=1 colspan=11>aCL IgG</td></tr><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Mean(FLU)</td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Within-Laboratory</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>2.33</td><td rowspan=1 colspan=1>0.13</td><td rowspan=1 colspan=1>5.5</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>0.18</td><td rowspan=1 colspan=1>7.8</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>5.64</td><td rowspan=1 colspan=1>0.29</td><td rowspan=1 colspan=1>5.1</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>0.28</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>0.42</td><td rowspan=1 colspan=1>7.4</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>8.77</td><td rowspan=1 colspan=1>0.37</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>0.32</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.49</td><td rowspan=1 colspan=1>5.6</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>26.15</td><td rowspan=1 colspan=1>1.41</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>1.42</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=1>2.00</td><td rowspan=1 colspan=1>7.6</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>66.29</td><td rowspan=1 colspan=1>2.53</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>2.22</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>2.71</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>4.32</td><td rowspan=1 colspan=1>6.5</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>201.45</td><td rowspan=1 colspan=1>7.94</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>5.58</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>10.65</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>14.40</td><td rowspan=1 colspan=1>7.2</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>265.15</td><td rowspan=1 colspan=1>11.06</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>10.94</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>19.96</td><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>25.30</td><td rowspan=1 colspan=1>9.5</td></tr></table>

<table><tr><td rowspan=1 colspan=11>aβ2GPI IgG</td></tr><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Mean(FLU)</td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Within-Laboratory</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>2.04</td><td rowspan=1 colspan=1>0.15</td><td rowspan=1 colspan=1>7.3</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>0.18</td><td rowspan=1 colspan=1>9.0</td><td rowspan=1 colspan=1>0.24</td><td rowspan=1 colspan=1>11.7</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>5.12</td><td rowspan=1 colspan=1>0.29</td><td rowspan=1 colspan=1>5.7</td><td rowspan=1 colspan=1>0.22</td><td rowspan=1 colspan=1>4.4</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.37</td><td rowspan=1 colspan=1>7.1</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>9.39</td><td rowspan=1 colspan=1>0.50</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>0.29</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>0.89</td><td rowspan=1 colspan=1>9.5</td><td rowspan=1 colspan=1>1.06</td><td rowspan=1 colspan=1>11.3</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>24.55</td><td rowspan=1 colspan=1>1.22</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>0.22</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.69</td><td rowspan=1 colspan=1>6.9</td><td rowspan=1 colspan=1>2.10</td><td rowspan=1 colspan=1>8.5</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>53.51</td><td rowspan=1 colspan=1>2.11</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>2.08</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>2.22</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>3.70</td><td rowspan=1 colspan=1>6.9</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>170.02</td><td rowspan=1 colspan=1>6.40</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>5.05</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>7.83</td><td rowspan=1 colspan=1>4.6</td><td rowspan=1 colspan=1>11.30</td><td rowspan=1 colspan=1>6.6</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>212.10</td><td rowspan=1 colspan=1>8.19</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>6.60</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>14.44</td><td rowspan=1 colspan=1>6.8</td><td rowspan=1 colspan=1>17.86</td><td rowspan=1 colspan=1>8.4</td></tr></table>

# Aptiva APS IgM Reagent

<table><tr><td rowspan=1 colspan=11>aCL IgM</td></tr><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Mean(FLU)</td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Within-Laboratory</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>2.93</td><td rowspan=1 colspan=1>0.12</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>0.25</td><td rowspan=1 colspan=1>8.5</td><td rowspan=1 colspan=1>0.28</td><td rowspan=1 colspan=1>9.7</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>5.54</td><td rowspan=1 colspan=1>0.15</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>0.27</td><td rowspan=1 colspan=1>4.9</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>10.67</td><td rowspan=1 colspan=1>0.34</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.50</td><td rowspan=1 colspan=1>4.7</td><td rowspan=1 colspan=1>0.62</td><td rowspan=1 colspan=1>5.8</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>21.94</td><td rowspan=1 colspan=1>0.59</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>0.55</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>0.51</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>0.95</td><td rowspan=1 colspan=1>4.3</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>56.16</td><td rowspan=1 colspan=1>1.30</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>0.47</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>3.07</td><td rowspan=1 colspan=1>5.5</td><td rowspan=1 colspan=1>3.36</td><td rowspan=1 colspan=1>6.0</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>73.51</td><td rowspan=1 colspan=1>2.25</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>1.23</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>3.06</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>3.99</td><td rowspan=1 colspan=1>5.4</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>116.09</td><td rowspan=1 colspan=1>2.62</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>2.55</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>5.90</td><td rowspan=1 colspan=1>5.1</td><td rowspan=1 colspan=1>6.94</td><td rowspan=1 colspan=1>6.0</td></tr></table>

<table><tr><td rowspan=1 colspan=11>aβ2GPI IgM</td></tr><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Mean(FLU)</td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Within-Laboratory</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>2.47</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>0.22</td><td rowspan=1 colspan=1>9.0</td><td rowspan=1 colspan=1>0.25</td><td rowspan=1 colspan=1>10.2</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>5.39</td><td rowspan=1 colspan=1>0.13</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>0.27</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>0.22</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>0.38</td><td rowspan=1 colspan=1>7.0</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>8.75</td><td rowspan=1 colspan=1>0.28</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>0.19</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>0.38</td><td rowspan=1 colspan=1>4.4</td><td rowspan=1 colspan=1>0.51</td><td rowspan=1 colspan=1>5.8</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>27.26</td><td rowspan=1 colspan=1>1.23</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>0.51</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>1.37</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>1.91</td><td rowspan=1 colspan=1>7.0</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>46.00</td><td rowspan=1 colspan=1>1.22</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>0.74</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>2.29</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>2.70</td><td rowspan=1 colspan=1>5.9</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>63.00</td><td rowspan=1 colspan=1>2.10</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>0.63</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>2.70</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>3.48</td><td rowspan=1 colspan=1>5.5</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>93.18</td><td rowspan=1 colspan=1>2.97</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>2.03</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>4.59</td><td rowspan=1 colspan=1>4.9</td><td rowspan=1 colspan=1>5.83</td><td rowspan=1 colspan=1>6.3</td></tr></table>

# Lot-to-Lot Imprecision:

The lot-to-lot imprecision of the Aptiva APS IgG Reagent and Aptiva APS IgM Reagent was evaluated by testing seven serum samples for aCL IgG and aβ2GPI IgG with three lots of the Aptiva APS IgG Reagent and six serum samples for aCL IgM and aβ2GPI IgM with three lots of the Aptiva APS IgM Reagent. Samples were tested in replicates of five, once a day, for five days using one instrument to generate a total of 75 data points for each sample. The results are summarized in the tables below.

# Aptiva APS IgG Reagent

<table><tr><td colspan="11" rowspan="1">aCL IgG</td></tr><tr><td colspan="1" rowspan="2">Sample</td><td colspan="1" rowspan="2">N</td><td colspan="1" rowspan="2">Mean(FLU)</td><td colspan="2" rowspan="1">Within-Day</td><td colspan="2" rowspan="1">Between-Day</td><td colspan="2" rowspan="1">Between-Lot</td><td colspan="2" rowspan="1">Total</td></tr><tr><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">%CV</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">%CV</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">%CV</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">%CV</td></tr><tr><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">75</td><td colspan="1" rowspan="1">1.61</td><td colspan="1" rowspan="1">0.08</td><td colspan="1" rowspan="1">5.2</td><td colspan="1" rowspan="1">0.07</td><td colspan="1" rowspan="1">4.4</td><td colspan="1" rowspan="1">0.12</td><td colspan="1" rowspan="1">7.2</td><td colspan="1" rowspan="1">0.16</td><td colspan="1" rowspan="1">9.9</td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">75</td><td colspan="1" rowspan="1">4.16</td><td colspan="1" rowspan="1">0.21</td><td colspan="1" rowspan="1">5.0</td><td colspan="1" rowspan="1">0.18</td><td colspan="1" rowspan="1">4.3</td><td colspan="1" rowspan="1">0.19</td><td colspan="1" rowspan="1">4.6</td><td colspan="1" rowspan="1">0.34</td><td colspan="1" rowspan="1">8.1</td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">75</td><td colspan="1" rowspan="1">19.71</td><td colspan="1" rowspan="1">0.98</td><td colspan="1" rowspan="1">5.0</td><td colspan="1" rowspan="1">0.99</td><td colspan="1" rowspan="1">5.0</td><td colspan="1" rowspan="1">2.17</td><td colspan="1" rowspan="1">11.0</td><td colspan="1" rowspan="1">2.58</td><td colspan="1" rowspan="1">13.1</td></tr><tr><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">75</td><td colspan="1" rowspan="1">51.11</td><td colspan="1" rowspan="1">2.67</td><td colspan="1" rowspan="1">5.2</td><td colspan="1" rowspan="1">1.63</td><td colspan="1" rowspan="1">3.2</td><td colspan="1" rowspan="1">6.06</td><td colspan="1" rowspan="1">11.9</td><td colspan="1" rowspan="1">6.82</td><td colspan="1" rowspan="1">13.3</td></tr><tr><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">75</td><td colspan="1" rowspan="1">124.49</td><td colspan="1" rowspan="1">5.93</td><td colspan="1" rowspan="1">4.8</td><td colspan="1" rowspan="1">5.92</td><td colspan="1" rowspan="1">4.8</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">8.37</td><td colspan="1" rowspan="1">6.7</td></tr><tr><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">75</td><td colspan="1" rowspan="1">168.77</td><td colspan="1" rowspan="1">7.11</td><td colspan="1" rowspan="1">4.2</td><td colspan="1" rowspan="1">8.61</td><td colspan="1" rowspan="1">5.1</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">11.17</td><td colspan="1" rowspan="1">6.6</td></tr><tr><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">75</td><td colspan="1" rowspan="1">285.27</td><td colspan="1" rowspan="1">10.73</td><td colspan="1" rowspan="1">3.8</td><td colspan="1" rowspan="1">5.73</td><td colspan="1" rowspan="1">2.0</td><td colspan="1" rowspan="1">11.38</td><td colspan="1" rowspan="1">4.0</td><td colspan="1" rowspan="1">16.66</td><td colspan="1" rowspan="1">5.8</td></tr><tr><td colspan="11" rowspan="1">aβ2GPI IgG</td></tr><tr><td colspan="1" rowspan="2">Sample</td><td colspan="1" rowspan="2">N</td><td colspan="1" rowspan="2">Mean(FLU)</td><td colspan="2" rowspan="1">Within-Day</td><td colspan="2" rowspan="1">Between-Day</td><td colspan="2" rowspan="1">Between-Lot</td><td colspan="2" rowspan="1">Total</td></tr><tr><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">%CV</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">%CV</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">%CV</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">%CV</td></tr><tr><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">75</td><td colspan="1" rowspan="1">1.97</td><td colspan="1" rowspan="1">0.10</td><td colspan="1" rowspan="1">5.0</td><td colspan="1" rowspan="1">0.13</td><td colspan="1" rowspan="1">6.7</td><td colspan="1" rowspan="1">0.03</td><td colspan="1" rowspan="1">1.7</td><td colspan="1" rowspan="1">0.17</td><td colspan="1" rowspan="1">8.5</td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">75</td><td colspan="1" rowspan="1">4.94</td><td colspan="1" rowspan="1">0.26</td><td colspan="1" rowspan="1">5.3</td><td colspan="1" rowspan="1">0.35</td><td colspan="1" rowspan="1">7.2</td><td colspan="1" rowspan="1">0.40</td><td colspan="1" rowspan="1">8.2</td><td colspan="1" rowspan="1">0.60</td><td colspan="1" rowspan="1">12.1</td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">75</td><td colspan="1" rowspan="1">23.39</td><td colspan="1" rowspan="1">1.08</td><td colspan="1" rowspan="1">4.6</td><td colspan="1" rowspan="1">1.24</td><td colspan="1" rowspan="1">5.3</td><td colspan="1" rowspan="1">1.10</td><td colspan="1" rowspan="1">4.7</td><td colspan="1" rowspan="1">1.98</td><td colspan="1" rowspan="1">8.5</td></tr><tr><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">75</td><td colspan="1" rowspan="1">58.42</td><td colspan="1" rowspan="1">3.18</td><td colspan="1" rowspan="1">5.5</td><td colspan="1" rowspan="1">2.47</td><td colspan="1" rowspan="1">4.2</td><td colspan="1" rowspan="1">3.87</td><td colspan="1" rowspan="1">6.6</td><td colspan="1" rowspan="1">5.59</td><td colspan="1" rowspan="1">9.6</td></tr><tr><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">75</td><td colspan="1" rowspan="1">100.56</td><td colspan="1" rowspan="1">5.55</td><td colspan="1" rowspan="1">5.5</td><td colspan="1" rowspan="1">6.40</td><td colspan="1" rowspan="1">6.4</td><td colspan="1" rowspan="1">5.21</td><td colspan="1" rowspan="1">5.2</td><td colspan="1" rowspan="1">9.94</td><td colspan="1" rowspan="1">9.9</td></tr><tr><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">75</td><td colspan="1" rowspan="1">144.20</td><td colspan="1" rowspan="1">6.89</td><td colspan="1" rowspan="1">4.8</td><td colspan="1" rowspan="1">9.57</td><td colspan="1" rowspan="1">6.6</td><td colspan="1" rowspan="1">10.69</td><td colspan="1" rowspan="1">7.4</td><td colspan="1" rowspan="1">15.92</td><td colspan="1" rowspan="1">11.0</td></tr><tr><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">75</td><td colspan="1" rowspan="1">213.10</td><td colspan="1" rowspan="1">8.78</td><td colspan="1" rowspan="1">4.1</td><td colspan="1" rowspan="1">5.46</td><td colspan="1" rowspan="1">2.6</td><td colspan="1" rowspan="1">21.18</td><td colspan="1" rowspan="1">9.9</td><td colspan="1" rowspan="1">23.57</td><td colspan="1" rowspan="1">11.1</td></tr></table>

# Aptiva APS IgM Reagent

<table><tr><td rowspan=1 colspan=11>aCL IgM</td></tr><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Mean(FLU)</td><td rowspan=1 colspan=2>Within-Day</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Lot</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>2.07</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>4.9</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>0.13</td><td rowspan=1 colspan=1>6.1</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>4.39</td><td rowspan=1 colspan=1>0.12</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>0.19</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>4.6</td><td rowspan=1 colspan=1>0.30</td><td rowspan=1 colspan=1>6.9</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>5.25</td><td rowspan=1 colspan=1>0.15</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>0.24</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>0.24</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>0.36</td><td rowspan=1 colspan=1>6.9</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>31.61</td><td rowspan=1 colspan=1>0.83</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>0.85</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>2.16</td><td rowspan=1 colspan=1>6.8</td><td rowspan=1 colspan=1>2.46</td><td rowspan=1 colspan=1>7.8</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>50.07</td><td rowspan=1 colspan=1>1.54</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>1.89</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>5.18</td><td rowspan=1 colspan=1>10.3</td><td rowspan=1 colspan=1>5.72</td><td rowspan=1 colspan=1>11.4</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>88.20</td><td rowspan=1 colspan=1>3.24</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>3.80</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>8.10</td><td rowspan=1 colspan=1>9.2</td><td rowspan=1 colspan=1>9.51</td><td rowspan=1 colspan=1>10.8</td></tr></table>

<table><tr><td rowspan=1 colspan=11>aβ2GPI IgM</td></tr><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Mean(FLU)</td><td rowspan=1 colspan=2>Within-Day</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Lot</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>1.57</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>5.6</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>0.12</td><td rowspan=1 colspan=1>7.6</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>4.62</td><td rowspan=1 colspan=1>0.15</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>0.25</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=1>0.15</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>0.33</td><td rowspan=1 colspan=1>7.0</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>5.73</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>0.28</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.34</td><td rowspan=1 colspan=1>6.0</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>24.76</td><td rowspan=1 colspan=1>0.61</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>0.68</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>1.86</td><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>2.07</td><td rowspan=1 colspan=1>8.4</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>54.40</td><td rowspan=1 colspan=1>1.63</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>2.45</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>4.54</td><td rowspan=1 colspan=1>8.3</td><td rowspan=1 colspan=1>5.41</td><td rowspan=1 colspan=1>9.9</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>80.53</td><td rowspan=1 colspan=1>2.52</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>3.27</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>7.35</td><td rowspan=1 colspan=1>9.1</td><td rowspan=1 colspan=1>8.43</td><td rowspan=1 colspan=1>10.5</td></tr></table>

# Site-to-Site Precision (Reproducibility):

The reproducibility of the Aptiva APS IgG Reagent and the Aptiva APS IgM Reagent was conducted at three different sites using seven serum samples for aCL IgG and aβ2GPI IgG and six serum samples for aCL IgM and aβ2GPI IgM. Samples were tested in replicates of five, once a day, for five days using one reagent lot to generate a total of 75 replicates per sample. The results are summarized below.

# Aptiva APS IgG Reagent

<table><tr><td rowspan=1 colspan=11>aCL IgG</td></tr><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Mean(FLU)</td><td rowspan=1 colspan=2>Within-Day</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Site</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>1.97</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>5.2</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>0.12</td><td rowspan=1 colspan=1>6.0</td><td rowspan=1 colspan=1>0.16</td><td rowspan=1 colspan=1>8.3</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>5.60</td><td rowspan=1 colspan=1>0.33</td><td rowspan=1 colspan=1>5.9</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>0.13</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>0.41</td><td rowspan=1 colspan=1>7.2</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>25.24</td><td rowspan=1 colspan=1>1.35</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>1.06</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>0.49</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>1.78</td><td rowspan=1 colspan=1>7.1</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>53.83</td><td rowspan=1 colspan=1>2.46</td><td rowspan=1 colspan=1>4.6</td><td rowspan=1 colspan=1>1.48</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>1.40</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>3.19</td><td rowspan=1 colspan=1>5.9</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>123.94</td><td rowspan=1 colspan=1>6.00</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>2.43</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>6.48</td><td rowspan=1 colspan=1>5.2</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>164.49</td><td rowspan=1 colspan=1>9.10</td><td rowspan=1 colspan=1>5.5</td><td rowspan=1 colspan=1>5.26</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>2.78</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>10.87</td><td rowspan=1 colspan=1>6.6</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>279.39</td><td rowspan=1 colspan=1>14.03</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>5.79</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>20.98</td><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>25.89</td><td rowspan=1 colspan=1>9.3</td></tr></table>

<table><tr><td rowspan=1 colspan=11>aβ2GPI IgG</td></tr><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Mean(FLU)</td><td rowspan=1 colspan=2>Within-Day</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Site</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>1.99</td><td rowspan=1 colspan=1>0.11</td><td rowspan=1 colspan=1>5.7</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>7.1</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>10.0</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>5.26</td><td rowspan=1 colspan=1>0.24</td><td rowspan=1 colspan=1>4.6</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>0.19</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>0.36</td><td rowspan=1 colspan=1>6.9</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>23.58</td><td rowspan=1 colspan=1>1.08</td><td rowspan=1 colspan=1>4.6</td><td rowspan=1 colspan=1>1.18</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>0.96</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>1.87</td><td rowspan=1 colspan=1>7.9</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>52.83</td><td rowspan=1 colspan=1>2.49</td><td rowspan=1 colspan=1>4.7</td><td rowspan=1 colspan=1>1.76</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>1.47</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>3.38</td><td rowspan=1 colspan=1>6.4</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>138.12</td><td rowspan=1 colspan=1>8.47</td><td rowspan=1 colspan=1>6.1</td><td rowspan=1 colspan=1>4.03</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>7.36</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>11.92</td><td rowspan=1 colspan=1>8.6</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>161.78</td><td rowspan=1 colspan=1>6.16</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>4.09</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>10.78</td><td rowspan=1 colspan=1>6.7</td><td rowspan=1 colspan=1>13.07</td><td rowspan=1 colspan=1>8.1</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>217.27</td><td rowspan=1 colspan=1>9.54</td><td rowspan=1 colspan=1>4.4</td><td rowspan=1 colspan=1>4.86</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>12.35</td><td rowspan=1 colspan=1>5.7</td><td rowspan=1 colspan=1>16.35</td><td rowspan=1 colspan=1>7.5</td></tr></table>

# Aptiva APS IgM Reagent

<table><tr><td rowspan=1 colspan=11>aCL IgM</td></tr><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Mean(FLU)</td><td rowspan=1 colspan=2>Within-Day</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Site</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>2.16</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>4.6</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>6.7</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>4.56</td><td rowspan=1 colspan=1>0.16</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>0.19</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.24</td><td rowspan=1 colspan=1>5.4</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>6.68</td><td rowspan=1 colspan=1>0.28</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>0.19</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>0.33</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>0.47</td><td rowspan=1 colspan=1>7.1</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>40.83</td><td rowspan=1 colspan=1>1.47</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>1.33</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>3.56</td><td rowspan=1 colspan=1>8.7</td><td rowspan=1 colspan=1>4.07</td><td rowspan=1 colspan=1>10.0</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>57.09</td><td rowspan=1 colspan=1>2.30</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>1.61</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>4.83</td><td rowspan=1 colspan=1>8.5</td><td rowspan=1 colspan=1>5.59</td><td rowspan=1 colspan=1>9.8</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>92.71</td><td rowspan=1 colspan=1>4.27</td><td rowspan=1 colspan=1>4.6</td><td rowspan=1 colspan=1>2.36</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>8.24</td><td rowspan=1 colspan=1>8.9</td><td rowspan=1 colspan=1>9.58</td><td rowspan=1 colspan=1>10.3</td></tr></table>

<table><tr><td rowspan=1 colspan=1>apzoliigivi</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Mean(FLU)</td><td rowspan=1 colspan=2>Within-Day</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Site</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>1.56</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>5.9</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>4.63</td><td rowspan=1 colspan=1>0.17</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>0.18</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>0.28</td><td rowspan=1 colspan=1>6.2</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>6.11</td><td rowspan=1 colspan=1>0.24</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>0.36</td><td rowspan=1 colspan=1>5.9</td><td rowspan=1 colspan=1>0.47</td><td rowspan=1 colspan=1>7.8</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>35.89</td><td rowspan=1 colspan=1>1.25</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>1.46</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>3.26</td><td rowspan=1 colspan=1>9.1</td><td rowspan=1 colspan=1>3.78</td><td rowspan=1 colspan=1>10.5</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>55.66</td><td rowspan=1 colspan=1>2.28</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>1.92</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>4.78</td><td rowspan=1 colspan=1>8.6</td><td rowspan=1 colspan=1>5.64</td><td rowspan=1 colspan=1>10.1</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>82.78</td><td rowspan=1 colspan=1>3.71</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>2.20</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>7.25</td><td rowspan=1 colspan=1>8.8</td><td rowspan=1 colspan=1>8.44</td><td rowspan=1 colspan=1>10.2</td></tr></table>

The linearity of the analytical measuring interval (AMI) was evaluated for the Aptiva APS IgG Reagent and the Aptiva APS IgM Reagent according to CLSI EP06-Ed2.

For the Aptiva APS IgG Reagent, five overlapping dilution series to cover the AMI of each of the aCL IgG and aβ2GPI IgG assays were prepared by mixing human serum samples with high antibody concentrations and samples with low antibody concentrations. Each sample was tested in duplicate using one lot of the Aptiva APS IgG Reagent. The overall testing range for linearity study is from 0.11–382.20 FLU for aCL IgG assay, and 0.11–301.21 FLU for a aβ2GPI IgG. The percent deviation from the weighted least squares regression analysis was used to assess the fit of the regression for each sample and each analyte. The data support the linearity of AMI of 0.29–328.94 FLU for the aCL IgG assay and the AMI of 0.21–256.70 FLU for the aβ2GPI IgG assay, as part of the Aptiva APS IgG Reagent.

For Aptiva APS IgM Reagent, four overlapping dilution series to cover portions of the AMI of each of the aCL IgM and aβ2GPI IgM assays were prepared by mixing human serum samples with high antibody concentrations and samples with low antibody concentrations. Each sample was tested in duplicate using one lot of the Aptiva APS IgM Reagent. The overall testing range for linearity study is from 0.04–118.12 FLU for aCL IgM assay, and 0.04–102.10 FLU for a aβ2GPI IgM. The percent deviation from the weighted least squares regression analysis was used to assess the fit of the regression for each sample and each analyte. The data support the linearity of AMI of 0.10–114.68 FLU for the aCL IgM assay and the AMI of 0.10–95.86 FLU for the aβ2GPI IgM assay, as part of the Aptiva APS IgM Reagent.

# 3. Hook effect

The hook effect for Aptiva APS IgG Reagent and Aptiva APS IgM Reagent on the Aptiva System was evaluated by testing high positive serum samples for each device: two high aCL IgG samples and two high aβ2GPI IgG samples for the Aptiva APS IgG Reagent; two high aCL IgM samples and two high aβ2GPI IgM samples for the Aptiva APS IgM Reagent.

For the Aptiva APS IgG Reagent, no antigen excess hook effect was observed up to 2645.36 FLU for aCL IgG and 1790.48 FLU for aβ2GPI IgG.

For the Aptiva APS IgM Reagent, no hook effect was observed up to 167.25 FLU for aCL IgM and 126.13 FLU for the aβ2GPI IgM.

4. Analytical Specificity/Interference:

# Interference

An interference study was performed according to CLSI EP07-A2 for the Aptiva APS IgG Reagent and the Aptiva APS IgM Reagent. A set of three human serum specimens— one positive, one around the cut-off and one negative sample for each assay were used to prepare interferent spiked samples or corresponding control samples without the interfering

substance. All samples were tested in five replicates using the Aptiva APS IgG Reagent and the Aptiva APS IgM Reagent. The percent recovery for each sample spiked with the potential interfering substance was calculated by comparing its result to that of the corresponding control sample without the interfering substance. Based on the results, the following tables display the highest concentration at which no interference was observed for the Aptiva APS IgG Reagent and IgM Reagent assays.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Aptiva APS IgG Reagent(aCL IgG / aβ2GPI IgG)</td><td rowspan=1 colspan=1>Aptiva APS IgM Reagent(aCL IgM / aβ2GPI IgM)</td></tr><tr><td rowspan=1 colspan=1>Interferent</td><td rowspan=1 colspan=2>Concentration without Interference</td></tr><tr><td rowspan=1 colspan=3>Endogenous</td></tr><tr><td rowspan=1 colspan=1>Bilirubin, Conjugated</td><td rowspan=1 colspan=1>1.0 mg/mL</td><td rowspan=1 colspan=1>1.0 mg/mL</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>10.00 g/L</td><td rowspan=1 colspan=1>10.00 g/L</td></tr><tr><td rowspan=1 colspan=1>Triglyceride</td><td rowspan=1 colspan=1>1000.0 mg/dL</td><td rowspan=1 colspan=1>1000.0 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Cholesterol</td><td rowspan=1 colspan=1>332.5 mg/dL</td><td rowspan=1 colspan=1>332.5 mg/dL</td></tr><tr><td rowspan=1 colspan=1>RF IgM</td><td rowspan=1 colspan=1>153.4 IU/mL</td><td rowspan=1 colspan=1>153.4 IU/mL</td></tr><tr><td rowspan=1 colspan=1>Human IgG</td><td rowspan=1 colspan=1>20.0 mg/mL</td><td rowspan=1 colspan=1>20.0 mg/mL</td></tr><tr><td rowspan=1 colspan=1>Exogenous</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Ibuprofen</td><td rowspan=1 colspan=1>21.9 mg/dL</td><td rowspan=1 colspan=1>21.9 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Warfarin</td><td rowspan=1 colspan=1>7.5 mg/dL</td><td rowspan=1 colspan=1>7.5 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Prednisone</td><td rowspan=1 colspan=1>0.0099 mg/dL</td><td rowspan=1 colspan=1>0.0099 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Acetaminophen</td><td rowspan=1 colspan=1>15.6 mg/dL</td><td rowspan=1 colspan=1>15.6 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Aspirin</td><td rowspan=1 colspan=1>3.00 mg/dL</td><td rowspan=1 colspan=1>3.00 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Hydroxychloroquine</td><td rowspan=1 colspan=1>0.465 mg/dL</td><td rowspan=1 colspan=1>0.465 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Omeprazole</td><td rowspan=1 colspan=1>0.840 mg/dL</td><td rowspan=1 colspan=1>0.840 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Simvastatin</td><td rowspan=1 colspan=1>0.168 mg/dL</td><td rowspan=1 colspan=1>0.168 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Heparin</td><td rowspan=1 colspan=1>330 units/dL</td><td rowspan=1 colspan=1>330 units/dL</td></tr></table>

# 5. Assay Reportable Range:

The reportable range for the Aptiva APS $\mathrm { I g G }$ Reagent and Aptiva APS $\mathrm { I g M }$ Reagent is the same as the analytical measuring interval (AMI) for both devices. The AMI for each assay is shown in the table below:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Analytical Measuring Interval</td></tr><tr><td rowspan=1 colspan=2>Aptiva APG IgG Reagent</td></tr><tr><td rowspan=1 colspan=1>aCL IgG</td><td rowspan=1 colspan=1>0.29−328.94FLU</td></tr><tr><td rowspan=1 colspan=1>aβ2GPI IgG</td><td rowspan=1 colspan=1>0.21—256.70 FLU</td></tr><tr><td rowspan=1 colspan=2>Aptiva APG IgM Reagent</td></tr><tr><td rowspan=1 colspan=1>aCL IgM</td><td rowspan=1 colspan=1>0.10 - 114.68 FLU</td></tr><tr><td rowspan=1 colspan=1>aβ2GPI IgM</td><td rowspan=1 colspan=1>0.10 - 95.86 FLU</td></tr></table>

6. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods):

There is no international reference material for anti-cardiolipin antibodies and anti- $\cdot \beta 2$ -GPI antibodies. Calibrator and control values are directly traceable to in-house reference materials that are used to create the master curves for each assay of the Aptiva APS IgG Reagent and the Aptiva APS IgM Reagent.

# Stability:

a. Reagent shelf-life stability: An on-going real-time stability and an accelerated stability study were conducted to establish shelf-life stability for the Aptiva APS IgG Reagent and the Aptiva APS IgM Reagent. The study required testing at least three serum samples at different levels for each assay using three lots of reagents at different timepoints. The collected data showed the initial shelf-life of 9 months for the Aptiva APS IgG Reagent and 7 months for the Aptiva IgM Reagent when stored at $2 { - } 8 ^ { \circ } \mathrm { C }$ .

b. Reagent in-use (on-board) stability: An initial in-use stability for the Aptiva APS IgG Reagent and Aptiva APS IgM Reagent was conducted by testing multiple samples with different assay levels at different time points using the reagent stored on board. The inuse (on-board) stability of the Aptiva APS IgG and Aptiva APS IgM Reagents was set at 28 days, with a 14-day recalibration.

c. Reagent shipping stability: A transport simulation study was performed to assess the shipping stability of the Aptiva APS IgG Reagent and the Aptiva APS IgM Reagent kits during transport. The study was performed under simulated conditions that the products may potentially be exposed to during transport. The collected data support the reagent packaging mitigates the potential impact of temperature stressing during transport.

d. Sample stability: Five serum samples with different antibody levels were stored at various storage temperatures and tested with the Aptiva APS IgG Reagent and the Aptiva APS IgM Reagent at various timepoints. The collected data showed that the sample can be stored up to 14 days at $2 { - } 8 ^ { \circ } \mathrm { C }$ , up to 48 hours at room temperature $( 2 0 – 2 6 ^ { \circ } \mathrm { C } )$ , and up to five freeze/thaw cycles when stored at ${ } _ { - 2 0 } \mathrm { { } ^ { \circ } C }$ .

7. Detection Limit:

Limit of Blank (LoB), Limit of Detection (LoD), and Limit of Quantitation (LoQ) were assessed for each analyte in the Aptiva APS IgG Reagent and the Aptiva APS IgM Reagent following CLSI EP17-A2.

# LoB:

To determine the LoB, four blank samples were run in five replicates, once a day for three days using two reagent lots, for a total of 60 data points per lot. The LoB was determined for each assay, on each reagent lot separately, at the $9 5 ^ { \mathrm { t h } }$ percentile using the non-parametric method for all analyses. The higher LoB result between the two lots was selected for the final LoB value.

# LoD:

To determine the LoD for each analyte, four low level samples were assayed in five replicates, twice per day for three days using two reagent lots, to generate a total of 120 data points for each assay on each reagent lot. The LoD was calculated as the $\mathrm { L o B } + 1 . 6 5 \mathrm { x } \mathrm { S I }$ D of the replicates for the samples separately for each assay on each reagent lot and the highest LoD result was selected for the final LoD value.

# LoQ:

To determine the LoQ for each analyte, four low level samples (different from LoD study) were run in five replicates, twice per day for three days using two reagent lots, to generate 120 data points for each assay on each reagent lot. The LoQ was determined separately for each assay on each reagent lot by calculating the total imprecision of each sample. The LoQ was defined as the lowest concentration level that meets the within-laboratory imprecision of $< 2 0 \%$ for each lot. The greatest LoQ across the two lots was set as the LoQ value and as the lower limit of the AMI for each assay.

The LoB, LoD, and LoQ for the Aptiva APS IgG Reagent and the Aptiva APS IgM Reagent are summarized in the following table:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>LoB(FLU)</td><td rowspan=1 colspan=1>LoD(FLU)</td><td rowspan=1 colspan=1>LoQ(FLU)</td></tr><tr><td rowspan=1 colspan=4>Aptiva APS IgG Reagent</td></tr><tr><td rowspan=1 colspan=1>aCL IgG</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>0.29</td></tr><tr><td rowspan=1 colspan=1>aβ2GPI IgG</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>0.21</td></tr><tr><td rowspan=1 colspan=4>Aptiva APS IgM Reagent</td></tr><tr><td rowspan=1 colspan=1>aCL IgM</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>0.10</td></tr><tr><td rowspan=1 colspan=1>aβ2GPI IgM</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>0.10</td></tr></table>

# 8. Assay Cut-Off:

The following cut-off is used for the aCL IgG, aβ2GPI IgG assays in the Aptiva APS IgG Reagent and aCL IgM and aβ2GPI IgM assays in the Aptiva APS IgM Reagent:

Positive: ${ \ge } 5 . 0 0$ FLU Negative: $< 5 . 0 0$ FLU

The cut-off was established based on greater than the 99th percentile of the results obtained on the reference healthy population.

# B Comparison Studies:

1. Method Comparison with Predicate Device:

Samples for the Aptiva APS IgG and Aptiva APS IgM method comparison analysis included serum samples from the clinical validation study (see VII.C) that display results within the analytical measuring range of the assay and the respective predicate device(s). Positive percent agreement (PPA), negative percent agreement (NPA), and total percent agreement (TPA) with $9 5 \%$ confidence intervals $( 9 5 \% C \mathrm { I } )$ were calculated for each analyte comparison, excluding values that were outside of the measuring ranges of either assay. The results are summarized in the following tables:

# Aptiva APS IgG Reagent

<table><tr><td rowspan=1 colspan=5>Method comparison (aCL IgG vs. the predicate device)</td></tr><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>HemosIL AcuStar Cardiolipin IgG(Predicate)</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>Aptiva APS IgGPositive (≥5.0 FLU)Reagent(aCL IgG)</td><td rowspan=1 colspan=1>Aptiva APS IgGPositive (≥5.0 FLU)</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>38</td></tr><tr><td rowspan=1 colspan=1>Negative (&lt;5.0 FLU)</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>157</td><td rowspan=1 colspan=1>164</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>38</td><td rowspan=1 colspan=1>164</td><td rowspan=1 colspan=1>202</td></tr><tr><td rowspan=1 colspan=5>PPA: 81.6% (31/38) (95% CI: 66.690.8%)NPA: 95.7% (157/164) (95% CI: 91.5-97.9%)TPA: 93.1% (188/202) (95% CI: 88.7-95.8%)</td></tr></table>

<table><tr><td rowspan=1 colspan=5>Method comparison (aβ2GPI IgG vs. the predicate device)</td></tr><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>QUANTA Lite aβ2GPI IgG ELISA(Predicate)</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>Aptiva APS IgG Positive (≥5.0 FLU)Reagent(aβ2GPI IgG)</td><td rowspan=1 colspan=1>Aptiva APS IgG Positive (≥5.0 FLU)</td><td rowspan=1 colspan=1>44</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>50</td></tr><tr><td rowspan=1 colspan=1>Negative (&lt;5.0 FLU)</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>58</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>58</td><td rowspan=1 colspan=1>108</td></tr><tr><td rowspan=1 colspan=5>PPA: 88.0% (44/50) (95% CI: 76.294.4%)NPA: 89.7% (52/58) (95% CI: 79.295.2%)TPA: 88.9% (96/108) (95% CI: 81.6-93.5%)</td></tr></table>

# Aptiva APS IgM Reagent

<table><tr><td colspan="5" rowspan="1">Method comparison (aCL IgM vs. the predicate device)</td></tr><tr><td colspan="2" rowspan="2"></td><td colspan="3" rowspan="1">HemosIL AcuStar Cardiolipin IgM(Predicate)</td></tr><tr><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Total</td></tr><tr><td colspan="1" rowspan="3">Aptiva APS IgM Positive (≥5.0 FLU)Reagent(aCL IgM)</td><td colspan="1" rowspan="1">Aptiva APS IgM Positive (≥5.0 FLU)</td><td colspan="1" rowspan="1">40</td><td colspan="1" rowspan="1">37</td><td colspan="1" rowspan="1">77</td></tr><tr><td colspan="1" rowspan="1">Negative (&lt;5.0 FLU)</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">339</td><td colspan="1" rowspan="1">345</td></tr><tr><td colspan="1" rowspan="1">Total</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">376</td><td colspan="1" rowspan="1">422</td></tr><tr><td colspan="5" rowspan="1">PPA: 87.0% (40/46) (95% CI: 74.3-93.9%)NPA: 90.2% (339/376) (95% CI: 86.792.8%)TPA: 89.8% (379/422) (95% CI: 86.6-92.3%)</td></tr><tr><td colspan="5" rowspan="1">Method comparison (aβ2GPI IgM vs. the predicate device)</td></tr><tr><td colspan="2" rowspan="2"></td><td colspan="3" rowspan="1">HemosIL AcuStar anti-β2 Glycoprotein-I IgM(Predicate)</td></tr><tr><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Total</td></tr><tr><td colspan="1" rowspan="3">Aptiva APS IgMReagent(aβ2GPI IgM)</td><td colspan="1" rowspan="1">Positive (≥5.0 FLU)</td><td colspan="1" rowspan="1">24</td><td colspan="1" rowspan="1">34</td><td colspan="1" rowspan="1">58</td></tr><tr><td colspan="1" rowspan="1">Negative (&lt;5.0 FLU)</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">183</td><td colspan="1" rowspan="1">186</td></tr><tr><td colspan="1" rowspan="1">Total</td><td colspan="1" rowspan="1">27</td><td colspan="1" rowspan="1">217</td><td colspan="1" rowspan="1">244</td></tr><tr><td colspan="5" rowspan="1">PPA: 88.9% (24/27) (95% CI: 71.9-96.1%)NPA: 84.3% (183/217) (95% CI: 78.9-88.6%)TPA: 84.8% (207/244) (95% CI: 79.9-88.8%)</td></tr></table>

2. Matrix Comparison:

Not applicable. Only human serum specimens are intended use sample type for the Aptiva APS IgG Reagent and Aptiva APS IgM Reagent.

# C Clinical Studies:

# Aptiva APS IgG Reagent

The clinical validation study for the Aptiva APS IgG Reagent was performed using a cohort of samples including a total of 526 characterized serum samples. This study cohort included 60 samples from patients with primary antiphospholipid syndrome (pAPS), 62 samples from patients with secondary antiphospholipid syndrome (sAPS), and 404 samples from patients with various types of autoimmune and infectious diseases. All samples were tested with the Aptiva APS $\mathrm { I g G }$ Reagent according to the instruction for use. The clinical performance of the Aptiva APS IgG Reagent as an aid in the diagnosis of APS are summarized in the following tables:

<table><tr><td rowspan=1 colspan=5>Clinical performance (aCL IgG)</td></tr><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Clinical Diagnosis</td></tr><tr><td rowspan=1 colspan=1>APS</td><td rowspan=1 colspan=1>Non-APS</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>Aptiva APS IgGReagent(aCL IgG)</td><td rowspan=1 colspan=1>Positive (≥5.0 FLU)</td><td rowspan=1 colspan=1>66</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>68</td></tr><tr><td rowspan=1 colspan=1>Negative (&lt;5.0 FLU)</td><td rowspan=1 colspan=1>56</td><td rowspan=1 colspan=1>402</td><td rowspan=1 colspan=1>458</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>122</td><td rowspan=1 colspan=1>404</td><td rowspan=1 colspan=1>526</td></tr><tr><td rowspan=1 colspan=5>Clinical Sensitivity:54.1% (66/122) (95% CI: 45.362.7%)Clinical Specificity:99.5% (402/404) (95% CI: 98.299.9%)</td></tr></table>

<table><tr><td rowspan=1 colspan=5>Clinical performance (aβ2GPI IgG)</td></tr><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Clinical Diagnosis</td></tr><tr><td rowspan=1 colspan=1>APS</td><td rowspan=1 colspan=1>Non-APS</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>Aptiva APS IgGReagent(aβ2GPI IgG)</td><td rowspan=1 colspan=1>Positive (≥5.0 FLU)</td><td rowspan=1 colspan=1>65</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>69</td></tr><tr><td rowspan=1 colspan=1>Negative (&lt;5.0 FLU)</td><td rowspan=1 colspan=1>57</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>457</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>122</td><td rowspan=1 colspan=1>404</td><td rowspan=1 colspan=1>526</td></tr><tr><td rowspan=1 colspan=5>Clinical Sensitivity:53.3% (65/122) (95% CI: 44.5-61.94%)Clinical Specificity:99.0% (400/404) (95% CI: 97.5-99.6%)</td></tr></table>

Distribution of target and differential disease samples and antibody positive rates are shown in the table below:

<table><tr><td rowspan=1 colspan=6>Aptiva APS IgG Reagent</td></tr><tr><td rowspan=2 colspan=1>Diagnostic Group</td><td rowspan=2 colspan=1>N=526</td><td rowspan=1 colspan=2>aCL IgG</td><td rowspan=1 colspan=2>aβ2GPI IgG</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>(%)</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>(%)</td></tr><tr><td rowspan=1 colspan=1>Target diagnosis</td><td rowspan=1 colspan=1>122</td><td rowspan=1 colspan=1>66</td><td rowspan=1 colspan=1>54.1%</td><td rowspan=1 colspan=1>65</td><td rowspan=1 colspan=1>53.3%</td></tr><tr><td rowspan=1 colspan=1>pAPS</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>55.0%</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>53.3%</td></tr><tr><td rowspan=1 colspan=1>sAPS</td><td rowspan=1 colspan=1>62</td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>53.2%</td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>53.2%</td></tr><tr><td rowspan=1 colspan=1>Differential diagnostic controls</td><td rowspan=1 colspan=1>404</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0.5%</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>1.0%</td></tr><tr><td rowspan=1 colspan=1>Infectious Disease</td><td rowspan=1 colspan=1>58</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1>PREPI</td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2.7%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2.7%</td></tr><tr><td rowspan=1 colspan=1>SLE no APS</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1>Systemic sclerosis</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>8.3%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>8.3%</td></tr><tr><td rowspan=1 colspan=1>Crohn&#x27;s Disease</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1>Ulcerative Colitis (UC)</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1>Rheumatoid Arthritis</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>4.8%</td></tr><tr><td rowspan=1 colspan=1>Fetal Loss no APS</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1>Thrombosis no APS</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1>ANCA-associated vasculitis (AAV)</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1>Autoimmune Thyroid</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1>Celiac Disease (CD)</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1>COVID-19 related thrombosis</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>5.0%</td></tr><tr><td rowspan=1 colspan=1>Hematologic malignancies</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1>Idiopathic thrombocytopenic purpura (ITP)</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1>Solid tumor malignancies</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1>Deep vein thrombosis</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td></tr></table>

# Aptiva APS IgM Reagent

The clinical validation study for the Aptiva APS IgM Reagent was performed using a cohort of samples including a total of 689 characterized serum samples. This study cohort included 219 samples from patients with primary antiphospholipid syndrome (pAPS), 72 samples from patients with secondary antiphospholipid syndrome (sAPS), and 398 samples from patients with various types of autoimmune and infectious diseases. All samples were tested with the Aptiva APS IgM Reagent according to the instruction for use. The clinical performance of the Aptiva APS IgM as an aid in the diagnosis of APS are summarized in the following tables:

<table><tr><td rowspan=1 colspan=5>Clinical performance (aCL IgM)</td></tr><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Clinical Diagnosis</td></tr><tr><td rowspan=1 colspan=1>APS</td><td rowspan=1 colspan=1>Non-APS</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>Aptiva APS IgMReagent(aCL IgM)</td><td rowspan=1 colspan=1>Positive (≥5.0 FLU)</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>90</td></tr><tr><td rowspan=1 colspan=1>Negative (&lt;5.0 FLU)</td><td rowspan=1 colspan=1>211</td><td rowspan=1 colspan=1>388</td><td rowspan=1 colspan=1>599</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>291</td><td rowspan=1 colspan=1>398</td><td rowspan=1 colspan=1>689</td></tr><tr><td rowspan=1 colspan=5>Clinical Sensitivity:27.5% (80/291) (95% CI: 22.732.9%)Clinical Specificity:97.5% (388/398) (95% CI: 95.4-98.6%)</td></tr></table>

<table><tr><td rowspan=1 colspan=5>Clinical performance (aβ2GPI IgM)</td></tr><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Clinical Diagnosis</td></tr><tr><td rowspan=1 colspan=1>APS</td><td rowspan=1 colspan=1>Non-APS</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>Aptiva APS IgMReagent(aβ2GPI IgM)</td><td rowspan=1 colspan=1>Positive (≥5.0 FLU)</td><td rowspan=1 colspan=1>72</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>78</td></tr><tr><td rowspan=1 colspan=1>Negative (&lt;5.0 FLU)</td><td rowspan=1 colspan=1>219</td><td rowspan=1 colspan=1>392</td><td rowspan=1 colspan=1>611</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>291</td><td rowspan=1 colspan=1>398</td><td rowspan=1 colspan=1>689</td></tr><tr><td rowspan=1 colspan=5>Clinical Sensitivity: 24.7% (72/291) (95% CI: 20.130.0%)Clinical Specificity: 98.5% (392/398) (95% CI: 96.899.3%)</td></tr></table>

Distribution of target and differential disease samples and antibody positive rates are shown in the table below:

<table><tr><td rowspan=1 colspan=6>Aptiva APS IgM Reagent</td></tr><tr><td rowspan=2 colspan=1>Diagnostic Group</td><td rowspan=2 colspan=1>N=689</td><td rowspan=1 colspan=2>aCL IgM</td><td rowspan=1 colspan=2>aβ2GPI IgM</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>(%)</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>(%)</td></tr><tr><td rowspan=1 colspan=1>Target diagnosis</td><td rowspan=1 colspan=1>291</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>27.5%</td><td rowspan=1 colspan=1>72</td><td rowspan=1 colspan=1>24.7%</td></tr><tr><td rowspan=1 colspan=1>pAPS</td><td rowspan=1 colspan=1>219</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>27.4%</td><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>23.7%</td></tr><tr><td rowspan=1 colspan=1>sAPS</td><td rowspan=1 colspan=1>72</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>27.8%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>27.8%</td></tr><tr><td rowspan=1 colspan=1>Differential diagnosis controls</td><td rowspan=1 colspan=1>398</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>1.5%</td></tr><tr><td rowspan=1 colspan=1>Infectious Disease</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1>Myositis</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>5.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1>Autoimmune Thyroiditis</td><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>8.6%</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>5.7%</td></tr><tr><td rowspan=1 colspan=1>Celiac Disease (CD)</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1>Ulcerative Colitis (UC)</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>5.3%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>5.3%</td></tr><tr><td rowspan=1 colspan=1>Rheumatoid Arthritis</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>7.7%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>7.7%</td></tr><tr><td rowspan=1 colspan=1>Atopic Dermatitis</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1>Fetal Loss no APS</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1>Pre-Eclampsia</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1>Thrombosis no APS</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>14.3%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>14.3%</td></tr><tr><td rowspan=1 colspan=1>ANCA-associated vasculitis (AAV)</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1>COVID-19 related thrombosis</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>5.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1>Hematologic malignancies</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1>Solid tumor malignancies</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>6.3%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>6.3%</td></tr><tr><td rowspan=1 colspan=1>Idiopathic thrombocytopenic purpura (ITP)</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1>Other disease controls</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1>Deep vein thrombosis</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>3.3%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td></tr></table>

# D Clinical Cut-Off:

Refer to assay cut-off.

# E Expected Values/Reference Range:

To determine the reference range of the Aptiva APS IgG and Aptiva APS IgM, a panel of 200 apparently healthy blood donors (106 females and 94 males, ages 18–70 years, and median age of 37 years) were tested following CLSI EP28-A3c. With the cut-off of 5.0 FLU, no samples tested positive for both the Aptiva APS IgG Reagent and the Aptiva APS IgM Reagent. The results are summarized in the following table:

<table><tr><td rowspan=1 colspan=1>Measurand</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Min(FLU)</td><td rowspan=1 colspan=1>Max(FLU)</td><td rowspan=1 colspan=1>Medium(FLU)</td><td rowspan=1 colspan=1>97.5th Percentile(FLU)</td></tr><tr><td rowspan=1 colspan=6>Aptiva APS IgG Reagent</td></tr><tr><td rowspan=1 colspan=1>aCL IgG</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>0.29</td><td rowspan=1 colspan=1>0.42</td><td rowspan=1 colspan=1>0.29</td><td rowspan=1 colspan=1>0.29</td></tr><tr><td rowspan=1 colspan=1>aβ2GPI IgG</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>0.21</td><td rowspan=1 colspan=1>0.47</td><td rowspan=1 colspan=1>0.21</td><td rowspan=1 colspan=1>0.21</td></tr><tr><td rowspan=1 colspan=6>Aptiva APS IgM Reagent</td></tr><tr><td rowspan=1 colspan=1>aCL IgM</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>2.54</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>0.51</td></tr><tr><td rowspan=1 colspan=1>aβ2GPI IgM</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>3.11</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>0.47</td></tr></table>

# VIII Proposed Labeling:

The labeling supports the finding of substantial equivalence for this device.

# IX Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.